A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.
One-fifth of patients with seemingly 'curable' pancreatic ductal adenocarcinoma (PDA) experience an early recurrence and death, receiving no definable benefit from a major operation. Some patients with advanced stage tumors are deemed 'unresectable' by conventional staging criter...
Main Authors: | Jordan M Winter, Laura H Tang, David S Klimstra, Murray F Brennan, Jonathan R Brody, Flavio G Rocha, Xiaoyu Jia, Li-Xuan Qin, Michael I D'Angelica, Ronald P DeMatteo, Yuman Fong, William R Jarnagin, Eileen M O'Reilly, Peter J Allen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3391218?pdf=render |
Similar Items
-
Correction: A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers.
by: Jordan M. Winter, et al.
Published: (2012-01-01) -
Correction: A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers
Published: (2012-01-01) -
Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract
by: Blumgart Leslie H, et al.
Published: (2009-05-01) -
Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
by: Sören Weidemann, et al.
Published: (2021-04-01) -
Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing.
by: Jian Zheng, et al.
Published: (2018-01-01)